Table 1 |.
Patient Characteristics | Total Gliosarcoma | Primary Gliosarcoma | Secondary Gliosarcoma | P-value |
---|---|---|---|---|
Baseline Demographics | 32 patients | 22 patients | 10 patients | |
Median Age, years (range) | 61.5 (33–77) | 62 (33–77) | 60.5 (39–70) | |
<50 | 25.0% | 27.3% | 20.0% | 0.307 |
≥50–≤70 | 40.6% | 31.8% | 60.0% | |
<70 | 34.4% | 40.9% | 20.0% | |
Median KPS (range) | 80% (60–100%) | 80% (60–90%) | 80% (70–100%) | - |
RTOG RPA Class | 0.559 | |||
III | - | - | - | |
IV | 76.9% | 85.7% | 66.7% | |
V/VI | 23.1% | 14.3% | 33.3% | |
Gender | 0.703 | |||
Male | 65.6% | 68.2% | 60% | |
Female | 34.4% | 31.8% | 40% | |
Ethnicity | 1.000 | |||
Caucasian | 85.7% | 83.3% | 90% | |
Hispanic | 14.3% | 16.7% | 10% | |
African-American | - | - | - | |
Asian | - | - | - | |
Tumor Characteristics | ||||
Neuroanatomic Localization | 0.045 | |||
Multilobar | 33.3% | 40.5% | 10.0% | |
Temporal | 23.3% | 30.0% | 10.0% | |
Frontal | 26.7% | 10.0% | 60.0% | |
Parietal | 10.0% | 10.0% | 10.0% | |
Occipital | 6.7% | 5.0% | 10.0% | |
Meningeal | 3.1% | 4.5% | 0.0% | |
Laterality | ||||
Unilateral | 90.6% | 100.0% | 70.0% | 0.024 |
Bilateral | 9.4% | - | 30.0% | |
Treatment Characteristics | ||||
Surgical Extent of Resection | ||||
Gross total resection | 56.7% | 63.6% | 30.0% | |
Near-total resection/Subtotal resection | 43.3% | 27.3% | 70.0% | |
Biopsy | - | - | - | |
Adjuvant Radiotherapy | ||||
Yes | 84.4% | 77.3% | 100.0%* | |
No | 15.6% | 22.7% | - | |
Median RT Dose, Gy (IQR) | 60 (40.5–60) | 59.4 (40.5–60) | 60 (45–60) | |
Temozolomide | ||||
Yes | 65.6% | 63.6% | 70.0%* | |
No | 34.4% | 36.4% | 30.0% | |
Salvage Treatments | ||||
Reresection | 41.9% | 47.6% | 30.0% | |
Stereotactic radiosurgery | 3.1% | 4.5% | 0.0% | |
Systemic therapy | 37.5% | 36.4% | 40.0% | |
Re-RT/Immunotherapy | 6.3% | 4.5% | 10.0% |
Refers to treatment following initial diagnosis of high-grade glioma prior to developing secondary gliosarcoma.